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Abstract
Being able to estimate a patient’s progress in the course of Alzheimer’s disease and predict-
ing future progression based on a number of observed biomarker values is of great interest
for patients, clinicians and researchers alike. In this work, an approach for disease progress
estimation is presented. Based on a set of subjects that convert to a more severe disease
stage during the study, models that describe typical trajectories of biomarker values in the
course of disease are learned using quantile regression. A novel probabilistic method is
then derived to estimate the current disease progress as well as the rate of progression of
an individual by fitting acquired biomarkers to the models. A particular strength of the
method is its ability to naturally handle missing data. This means, it is applicable even if indi-
vidual biomarker measurements are missing for a subject without requiring a retraining of
the model. The functionality of the presented method is demonstrated using synthetic and
—employing cognitive scores and image-based biomarkers—real data from the ADNI
study. Further, three possible applications for progress estimation are demonstrated to
underline the versatility of the approach: classification, construction of a spatio-temporal dis-
ease progression atlas and prediction of future disease progression.
Introduction
Alzheimer’s disease (AD), the most common cause of dementia, is a dynamic neurodegenera-
tive condition of which roughly 36 million patients suffer today. With the ageing population,
the worldwide prevalence is expected to rise to over 100 million by 2050 [1]. Patients diagnosed
with Mild Cognitive Impairments (MCI)—an early form of dementia—show first symptoms of
general memory loss. In the course of the disease, these symptoms are followed by behavioural
change and further cognitive and functional decline, such that patients become less and less
able to perform even basic tasks. As studies suggest, the annual conversion rate fromMCI to
AD lies between 10 and 15% [2]. However, there is considerable variability in the disease
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progression between patients diagnosed with dementia [3]. Clinicians, researchers, and
patients alike therefore often face two questions: How severe is the form of dementia? And how
fast will the progression of the disease be?
Estimating the current stage of the disease and predicting the rate of progression has been
the aim of many publications. Most approaches consider results of cognitive tests like the Mini
—mental State Examination (MMSE), the Alzheimer’s Disease Assessment Scale (ADAS), and
the Clinical Dementia Rating (CDR) as biomarkers that characterise disease progression. For
example, Doody et al. use the measured MMSE score together with the estimated duration of
symptoms to compute a pre-progression rate, that means the rate of decline prior to the first
physician visit [4]. Test subjects are then grouped in slow, intermediate and rapid progression.
Based on this, the future course of the disease is predicted [3].
In many approaches—see for example [5] for a detailed overview—Markov transition mod-
els and Cox proportional hazard model are employed to estimate disease progression. For
example, Neumann et al. [6] and Spackman et al. [7] estimate the probability of a transition
between discrete CDR states based on the Behaviour Rating Scale for Dementia (BRSD) while
considering explanatory variables like age, sex and the mental status of the patients. Similarly,
in the model proposed by Caro et al. [8], the probability of a patient needing full-time care or
dying within a given period of time is estimated using a Markov model with time dependent
hazard functions. However, as Green et al. conclude in their review, the main limitations of
these methods are “the use of a limited number of health states to capture events related to dis-
ease progression over time” and the fact that “a single symptom, such as cognition, is not able
to characterise AD progression” [5]. Stallard et al. further argue from a methodological point
of view that varying progression rates violate assumptions of Markov transition models and
that Cox regression models implicitly assume the predictors to be fixed for individual patients
(which, e.g., age and cognitive function are not) [9]. They therefore propose a longitudinal
Grade of Membership (L-GoM) model, in which MMSE, BRSD, education, alcohol use, and
other attributes are used to estimate the disease progression in three separate dimensions (cog-
nitive, clinical, and functional). This approach is further evaluated by Razlinghi et al. [10] to
predict the time to events such as full-time care, institutionalisation, or death.
Another important development in the field of progression estimation aims at deriving
meaningful biomarkers from image data to capture pathological changes of the brain structure.
This approach is based on the observation that neurodegeneration precedes clinical symptoms
[11] and therefore holds valuable information about early disease progression. For example,
Moradi et al. give a comprehensive overview on machine learning methods in which imaging
biomarkers are used to predict conversion from one disease stage to another [12]. Hua et al.
show that neuroimaging measures derived from tensor-based morphometry (TBM) can con-
siderably reduce the sample size required for progression estimation [13]. Sabuncu et al. use an
extended Cox regression model to associate longitudinal biomarkers derived fromMRI data
with the occurrence of clinical events [14]. In [15], a brain age gap estimation (BrainAGE)
score is computed based on typical atrophy patterns in MR images and employed to predict
conversion from MCI to AD. Another interesting approach is presented by Fonteijin et al. [16]
and later extended by Young et al. [17]. Here, an event-based model is used to determine the
order in which cerebrospinal fluid, image-based and cognitive biomarkers become abnormal.
This information can then be used to assign a subject to one of several discrete disease stages.
However, modelling disease progression by a number of discrete stages is a simplification of
a continuous process and entails some limitations. Jack et al., for example, argue that “evolving
diagnostic criteria must incorporate AD biomarkers but cannot proceed effectively without
accurate time-dependent models of those biomarkers” [18]. Availability of further knowledge
about the temporal offset between discrete states also simplifies the prediction of cognitive
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decline within a given period of time. To this end, some approaches have been developed that
regard the course of disease as a continuous progress. For example, Jack et al. analyse the shape
of typical biomarker trajectories depending on the MMSE score of the subject [19]. Yang et al.
assume an exponential-shaped trajectory of the ADAS score [20]. Based on the fact that study
entry time does not correspond to the start of the disease, they then estimate a temporal offset
γ indicating the disease progress of a subject by fitting its ADAS scores to this curve. Similarly,
Delor et al. [21] compute a disease onset time (DOT) by adjusting subjects according to their
CDR-SB (Sum of Boxes) score. While these methods make strong assumptions on the trajecto-
ries’ shapes, Donohue et al. only assume them to be smooth and monotone [22]. Shape param-
eters and temporal offset are then estimated in an alternating fashion by minimising the
residual sum of squares.
Rather than only focusing on the mean trajectory—as done in least squares regression—
quantile regression models the median and other quantile functions of a response variable in
dependency of the predictor variable [23]. The response is not required to be normal distrib-
uted, which is of particular interest for variables that show boundary effects (as, for example,
many cognitive test scores). In the context of Alzheimer’s disease, Sherwood et al. recently pro-
posed linear quantile regression to estimate the conditional percentiles of neuropsychological
test scores [24]. Li et al. model the episodic memory outcome (a composite score comprised of
six clinical neuropsychological tests) with age and time to AD diagnosis as covariates [25].
Their model is also linear but allows a single change-point at which the slope of the response
variable changes rapidly. While this assumption is reasonable for cognitive function, it is
unclear to which degree it holds for imaging-based biomarkers. Therefore, Schmidt-Richberg
et al. proposed to employ Vector Generalised Additive Models (VGAM’s) for quantile regres-
sion [26]. VGAM’s are based on vector smoothers, which means that smoothness is the only
assumption made on the shape of the curves. In contrast to [22], non-monotonic trajectories
(as arising, for example, from manifold learning) are allowed. However, application of this
technique requires a prior temporal alignment of the subjects. Similarly to [25], this is done
based on the time to AD diagnoses.
This work builds upon the preliminary results presented in [26] and employs VGAM’s vor
model estimation. Utilising the estimated quantile curves, a probabilistic model is derived to
compute a time warp that indicates the disease progress and the rate of progression of a subject
based on measured biomarker values. The approach is flexible with regard to the considered
biomarkers, which can be based on cognitive scores or neuroimaging, for instance. Moreover,
missing data is handled in a natural way. This means, the approach can be employed even if
the set of observed biomarkers is not complete. This work also adds a thorough evaluation of
the approach based on synthetic and real data to the results presented in [26]. Further, the
applicability is demonstrated for classification tasks, 4D atlas generation, as well as the predic-
tion of future biomarker values.
Methods
The presented approach of disease progression analysis is based on a set of quantitative mea-
surements of variables that have the potential to characterise disease progression. These mea-
surements could be biological markers (for example Aβ plaque deposition), results from
cognitive and functional tests, volumes of brain structures or any other kind of features derived
from medical imaging techniques. For the sake of simplicity, we refer to these measurements as
biomarkers (in an extended meaning of the term) in the remainder of this article.
Let ybsv denote biomarker values acquired from multiple subjects s 2 S = [1, . . ., nS] during
multiple visits v 2 Vs, with b 2 Bsv denoting the biomarker index. Each biomarker vector is
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associated with the time tsv 2 T ¼ Rþ of acquisition, measured in days after the ﬁrst (baseline)
visit ts1 = 0, as well as the diagnosis dsv that was given during each visit. In this work, dsv 2 {CN,
EMCI, LMCI, AD} is assumed with CN denoting cognitively normal subjects and EMCI and
LMCI early and late MCI, respectively. It is to be noted that the number of visits can vary for
each subject, Vs V = [1, . . ., nV]. Also, the biomarkers acquired at each visit might differ,
such that Bsv B = [1, . . ., nB].
The proposed method consists of two parts. In the first phase (following machine learning
methods referred to as training phase), “typical” trajectories of biomarkers in the course of dis-
ease progression are determined based on the values measured for a number of training sub-
jects. In the second phase, these models are employed to estimate how far test subjects have
progressed along the disease trajectory.
Model training
The model training phase aims at learning typical trajectories of biomarker values in the course
of the disease. Instead of just concentrating on the mean trajectories, also the variations of bio-
marker values in the cohort are of interest. That means, the probability that a certain biomarker
b has a value yb at a specified time point in the disease is to be determined. More technically,
each measured biomarker value ybsv is understood as an observation of a dependent variable Y
b
given an explanatory variable or covariate psv. Here, psv 2 P is called the disease progress, which
indicates how far the subject s has progressed in the continuum of the disease P at the time of
visit v. The notation of a disease progress is chosen over disease stage (cf. [17]) to emphasise
that the course of the disease is seen as a continuous progress rather than a sequence of discrete
stages. Thus, psv can be seen as an offset to some speciﬁed time point p = 0, for example disease
onset. In this work, P  R is simplistically assumed to be one-dimensional. The probability
density function (PDF) of Yb given p is then denoted by fYb (y|p).
A disease progression modelMðpÞ comprises the density functions of all biomarkers in B on
a domain P and is deﬁned as
MðpÞ ¼ fM1ðpÞ;    ;MnBðpÞg with MbðpÞ :¼ fYbðyjpÞ ð1Þ
for p 2 P. Another way of representing the model is by its q-quantile functions
ybqðpÞ :¼ inf fy 2 R : FYbðy j pÞ  qg; q 2 ð0; 1Þ;
where FYb (y|p) is the cumulative distribution function corresponding to fYb (y|p). For example,
yb0:5ðpÞ denotes the median trajectory. Moreover, qb(y, p) is deﬁned as the function that maps a
biomarker value y to the corresponding quantile at disease progress p.
The model training consists of two main steps. First, the training subjects have to be tempo-
rally aligned to establish correspondences between the time points of observation. Based on the
aligned data, progression models are then estimated using quantile regression to learn the PDF
fYb (y|p).
Temporal alignment of the training data. The temporal alignment aims at associating
the time points tsv of biomarker acquisition (measured in days after baseline) to the corre-
sponding disease progresses psv. In detail, the goal is to find a strict monotonically increasing
(and thereby order preserving) function τ(t) that maps the subject-specific acquisition time tsv
2 T to the population-based disease progression time psv 2 P, such that psv = τ(tsv). Following
[27], τ(t) is denoted as time warp in this work.
The main challenge of the model training is that the real progression of training subjects is
unknown. Therefore, the time point at which a more severe disease stage is first diagnosed by a
clinician is considered as indicator for the disease progress. In particular, the point of
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conversion t0s at which the diagnosis of subject s changes from MCI to AD is set to p = 0, that
means
psv ¼ tðt0s ; tsvÞ :¼ tsv  t0s ð2Þ
For this reason, the training set consists of all subjects that convert from one diagnosis to
another during the study (here, fromMCI to AD). To identify t0s , the index κ is determined,
such that vκ and vκ+1 are the visits with the last MCI and the ﬁrst AD diagnosis, i.e. dsvκ = MCI,
dsvκ+1 = AD. The time point of conversion is then assumed to be the average of these two visits:
t0s :¼
tsvk þ tsvkþ1
2
:
The set of all aligned training samples is illustrated exemplarily for the CDR-SB in Fig 1A. In
the current model, training subjects are assumed to progress with the same rate in the course of
disease.
Model training using VGAM. The aim of this section is to estimate the conditional den-
sity functions fYb for arbitrary biomarkers. In this context, Jack et al. assume a sigmoidal shape
of functional, biological and imaging-based biomarkers [11]. Donohue et al., however, rather
observe linear or near-linear shapes of several trajectories [22]. Other biomarkers, such as coor-
dinates obtained from manifold learning, follow arbitrary trajectories not even necessarily
Fig 1. Illustration of the model training process on the example of the CDR-SB cognitive score. (A)
First, sample points are temporally aligned according to the point on conversion. The colours indicate MCI
(yellow) or AD (red) diagnosis. (B) The progression model is then estimated using quantile regression. The
quantile functions ybqðpÞ with q 2 {0.1, 0.25, 0.5, 0.75, 0.9} are visualised. (C) To increase the domain P, the
model is then extrapolated. For each solid vertical line, the corresponding PDF is given in Fig 1D. (D)
Illustration of the corresponding density functions fYb (y|p), that indicate the probability of values y at given
progresses p.
doi:10.1371/journal.pone.0153040.g001
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monotonic [28]. In contrast to logistic or exponential regression as employed—for example—
in [20], the approach followed in this work aims to make no assumptions on the shape of bio-
marker trajectories besides smoothness and thereby allows to treat all biomarkers in a unified
way. To this end, quantile curves are estimated via vector generalised additive models
(VGAMs) [29].
Technically, the goal of VGAMs is to estimate fY (y|p), the conditional probability density
function (PDF) of a dependent variable Y given an explanatory variable (or covariate) p. It is
assumed that fY can be described by some smooth function gY with
fYðy j pÞ ¼ gYðy; Z1ðpÞ;    ; ZMðpÞÞ:
Here, ηm are the predictors given by
ZmðpÞ ¼ bm þ fmðpÞ;
where βm are intercept values and fm are smooth functions of the covariate estimated by cubic
smoothing splines, or vector smoothers [30]. In contrast to parametric vector generalised linear
models (VGLM), where ηm(p) = βm0 + βm1 p are linear predictors, the relation between the p
and η is only constrained to be smooth in additive models. This allows a more ﬂexible estima-
tion of the trajectories by capturing non-linear features of the data.
To model a normal distribution of Y, gY could be given by a Gaussian function with η1 being
the mean and η2 the standard deviation. However, some biomarkers regarded in this work can-
not take negative values and the corresponding density functions are therefore likely to be
skewed. Therefore, the LMS (Lambda, Mu, Sigma) method by Cole et al. [31] is employed for
quantile regression. Here, skewness is allowed by applying the Yeo-Johnson transformation
ψ(y, λ) with
cðy; lÞ ¼
ððy þ 1ÞlÞ=l ðy  0; l 6¼ 0Þ
logðy þ 1Þ ðy  0; l ¼ 0Þ
ððy þ 1Þ2l  1Þ=ð2 lÞ ðy < 0; l 6¼ 2Þ
logðy þ 1Þ ðy < 0; l ¼ 2Þ
8>>>><
>>>>:
on the response, such that the values of the transformed dependent variable approximate nor-
mality [32]. The density function gY at p then depends on three predictors λ(p) := η1(p), μ(p) :=
η2(p), and σ(p) := η3(p), and is given by
gYðy; lðpÞ; mðpÞ; sðpÞÞ ¼
1
sðpÞ
cðy; lðpÞÞ  mðpÞ
sðpÞ
 
 ðjyj þ 1ÞsgnðyÞðlðpÞ1Þ
with ϕ() being a standard normal distribution. The corresponding q-quantile curves are then
given by
yqðpÞ ¼ c1ðlðpÞ; mðpÞ þ ZqsðpÞÞ: ð3Þ
Here, the factor Zq :=F
−1(q) relates the quantile q 2 (0, 1) to the corresponding standard devia-
tion σ using the percent point function (PPF) ϕ−2, which is the inverse of the cumulative distri-
bution function (CDF) F of a normal distribution. For example, the q = 0.5 quantile
corresponds to the median with Z0.5 = 0. A thorough and more formal introduction to VGAMs
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can be found in [29]. The implementation is based on the R package ‘VGAM’ (http://cran.r-
project.org/web/packages/VGAM/index.html).
One particular drawback of using VGAMs is that the domain P ofMbðpÞ is limited to the
progress interval contained in the sample set. This means P is given by P = [p−, p+], with p− :=
mins, v(psv) and p+ := maxs, v(psv) being the earliest and latest observed progress, respectively.
Therefore, an approach to extrapolate the model by extending the underlying predictor func-
tions is presented in appendix A1 and visualised in Fig 1C. As a result, P ¼ R is assumed in the
following.
The estimated percentile curves obtained by VGAM and the corresponding probability den-
sity functions of the CDR-SB are exemplarily visualised in Fig 1B and 1D, respectively.
Progress estimation
Generally, the point of conversion t0s is unknown because it is not contained in the set of obser-
vations (or—in case of healthy and MCI subjects—has not yet been reached) and Eq (2) cannot
be employed. Progress estimation is therefore understood as the task of ﬁnding the most likely
time warp τ(t) that optimally ﬁts the biomarkers values measured for a test subject into the
modelM.
Let ts = (ts1, . . ., tsnV)
T be the vector containing the time points of all visits of subject s and
τ(ts) = (τ(ts1), . . ., τ(tsnV))
T. Let further ys = (ysv)v 2 Vs be the vector with the biomarkers mea-
sured for s with ysv ¼ ðybsvÞb2Bsv denoting the biomarkers acquired at visit v. Based on ts, the
most probable time warp τ^ s given ys is determined by maximising the logarithm of the likeli-
hood function LðτðtsÞ j ysÞ. This means
τ^ s :¼ argmax
τ
logLðτðtsÞ j ysÞ ¼ argmax
τ
log fYðys j tðtsÞÞ ð4Þ
with Y ¼ ðY1;    ;YnBÞ. The joint probability of all observations ybsv given τ is then
fYðys j τðtsÞÞ ¼
Y
v2Vs
fYðysv j τðtsvÞÞ ¼
Y
v2Vs
Y
b2Bsv
fYbðybsv j τðtsvÞÞ:
whereat all biomarker observations are assumed to be independent of each other.
Two different parameterisations of τ are regarded. The most simple way is given by the
translational time warp
τðp0; tÞ :¼ p0 þ t: ð5Þ
Here, the disease progress (DP) p0 2 R is a simple offset that indicates how far the subject is
progressed in the course of the disease at the time point of the ﬁrst visit, measured in days rela-
tive to the point of conversion from MCI to AD. However, this simple model cannot accom-
modate for different rates of progression, which are known to exist between subjects [4]. If |
Vs|>1, the extended afﬁne time warp deﬁnition
τðp0; r; tÞ :¼ p0 þ rt ð6Þ
can be employed, where r 2 Rþ is a scaling factor indicating the disease progression rate
(DPR). The optimal values p^0s and r^ s for DP and DPR are then determined by maximising Eq
(4) over all p0 and r, meaning t^sðÞ≙ tðp^0s ; r^; Þ. The deﬁnition of other, more complex time
warps is possible but not regarded in this work. In the current implementation, Eq (4) is solved
with a simple exhaustive search.
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Materials
To evaluate the presented methods for model training and progress estimation, synthetic as
well as real data is considered.
Synthetic data
Artificial progression models fMbðpÞ are deﬁned to serve as ground truth in the experiments
on synthetic data. Using such models, biomarker values can be randomly sampled on P accord-
ing to their PDFs. Based on these samples, progression modelsMbðpÞ are learned and then
compared to the underlying model fMbðpÞ.
The synthetic models used in this work are defined by a median trajectory yb0:5ðpÞ (for exam-
ple, a linear, exponential or sigmoidal model) and a density function to account for intra- and
inter-subject variations. fMbðpÞ are deﬁned loosely based on clinical publications by Henne-
man et al. [33] and Coley et al. [34]. However, it is to be noted that the intention is not to opti-
mally describe realistic progression models, but rather to cover different density functions that
could similarly be observed “in the wild”. With this in mind, the synthetic models analysed in
this work represent the following three biomarkers:
• Hippocampal volume (HV): In [33], a mean hippocampal volume of 3,693(±572)mm3 and an
atrophy rate of 3.5% per year is reported for a pool of 142 subjects. Based on this data, a median
trajectory is defined as yHV0:5 ðpÞ ¼ 3693  0:965p=365. The underlying PDF is assumed to be
Gaussian, such that ~f YHVðyjpÞ :¼ðp; yHV0:5 ðpÞ; 572Þ, where ϕ(p, μHV(p), σHV) denotes a normal
distribution with time-varying mean (and median) μHV(p) and fixed standard deviation σHV.
• CDR-SB: Coley et al. [34] divide subjects in two groups with a Clinical Dementia Rating
(CDR) of 0.5 and 1-2, respectively. For these, CDR-SB (Clinical Dementia Rating: Sum of
Boxes) scores of 3.2(±0.9) and 7.9(±2.6) are reported. For the definition of a synthetic model,
the disease progression is arbitrarily assumed to equal -1095 (3 years before conversion) for
the first group and 1095 (3 years after conversion) for the latter. An exponential model (see
Table 1) is defined for the median trajectory such that yCDRSB0:5 ð1095Þ ¼ 3:2 and
yCDRSB0:5 ð1095Þ ¼ 7:9. Equally, a time-dependent standard variation σCDR-SB(p) is interpo-
lated by an exponential function. Since the CDR-SB is always positive, a Gaussian distribu-
tion of the values is unlikely and a gamma distribution is chosen instead:
~f YCDRSBðyjpÞ :¼Gðp; kðpÞ; yðpÞÞ. Shape and scale parameters k(p) and θ(p) are chosen such
that median and standard deviation of the PDF equal yCDRSB0:5 ðpÞ and σCDR-SB(p).
• MMSE: For the MMSE score, values of 23.2(±2.6) for the CDR 0.5 group and 18, 4(±4.0) for
the CDR 1-2 group are reported [34]. Based on these values, the model is defined using a neg-
ative Gamma distribution, such that values are bounded at a MMSE score of 30.
Table 1. Overview on the synthetic models with p0 := p + 1095.
Model Median trajectory yb0:5ðpÞ Noise model Sigma σb(p)
fMHV 3693*0.965p/365 Gaussian 572.0
fMCDRSB 3:2exp logð7:9=3:2Þ6365 p0  Gamma 0:9exp logð2:6=0:9Þ6365 p0 fMMMSE 30 6:8exp logð11:6=6:8Þ6365 p0  Gamma 2:6exp logð4:0=2:6Þ6365 p0 
doi:10.1371/journal.pone.0153040.t001
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The definitions are detailed in Table 1 and the resulting synthetic density functions visualised
in Fig 2.
Real data
Clinical evaluation is based on data from the Alzheimer’s Disease Neuroimaging Initiative
(ADNI). ADNI is a large-scale multi-site study that aims at analysing biomarkers from cogni-
tive tests, blood tests, tests of cerebrospinal fluid, and MRI/PET imaging with regard to their
ability to characterise the progression of AD.
For this study, all subjects enrolled in either ADNI1, ADNIGO or ADNI2 are considered
(based on the ADNIMERGE data base as of 30/01/2014). Participating subjects are categorised
as CN, EMCI, LMCI or AD (according to the NINCDS/ADRDA criteria). Levels of MCI (early
or late) are determined using the Wechsler Memory Scale Logical Memory II. For model train-
ing, all 248 subjects that converted fromMCI to AD during the study are selected. As detailed
below, the number of available biomarkers can vary between the training subjects. Data from
all available visits (between 2 and 11 visits over 96 months, median 6.0) is used for model train-
ing. The test set, in contrast, comprises the non-converting subjects for which all biomarkers
are present at baseline (bl), month 12 (m12) and month 24 (m24) visit to obtain consistent
results in all experiments. In total, these are 160 (89 male, 71 female) subjects classified as cog-
nitive normal (CN), 91 (50 male, 41 female) EMCI, 96 (64 male, 32 female) LMCI and 95 (49
male, 46 female) AD subjects.
The set B of biomarkers considered for the real data comprises cognitive scores and image-
based features detailed in the following. An age correction of the biomarker values is performed
using a linear regression on the baseline samples of all control subjects.
Cognitive scores Bcog: Subjects participating in the ADNI study are asked to perform a
number of cognitive tests at each visit and the results are directly used as biomarkers. These
tests comprise the Mini—mental State Examination (MMSE), the Alzheimer’s Disease Assess-
ment Scale (ADAS 11 and ADAS 13), the Functional Activities Questionnaire (FAQ), the Clin-
ical Dementia Rating—Sum of Boxes (CDR-SB), and the Rey Auditory Verbal Learning Test
(RAVLT). It is to be noted that not every test result is available for each visit, such that the
absolute number of available training samples varies between 1458 to 1480 samples from 248
subjects.
Volumes of brain structures Bvol: Further, the volumes of 35 distinct brain structures are
used as biomarkers. For this, MR scans are first automatically segmented into 134 regions
using the whole brain segmentation proposed by Ledig et al. [35], which is based on multi-atlas
label propagation with expectation-maximisation based refinement (MALPEM). Brain atlases
from the MICCAI 2012 Grand Challenge on Multi-Atlas Labeling (https://masi.vuse.
vanderbilt.edu/workshop2012) are employed. The corresponding manual expert
Fig 2. Illustration of the quantile functions of the synthetic models in blue. In grey, models
reconstructed from nsmp = 1000 random samples are shown.
doi:10.1371/journal.pone.0153040.g002
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segmentations are provided by Neuromorphometrics, Inc. (http://Neuromorphometrics.com)
under academic subscription. Here, the 30 atlas segmentations are transformed to an unseg-
mented scan and fused into a consensus probabilistic segmentation estimate using a local
weighting approach. The required nonrigid transformations are calculated using a robust regis-
tration method based on multi-level free form deformations [36]. All 134 probabilistic label
estimates are subsequently corrected for registration inaccuracies and further refined using
image intensity information.
To reduce the total number of models, cortical structures are fused to right and left cortex,
resulting in the 35 distinct anatomical regions listed in appendix A2. For procedural reasons,
only segmentations for images acquired before 20/11/2013 were available, such that the total
number of training samples for each structure is 955 from 247 subjects.
Biomarkers derived frommanifold learning Bml: Features obtained fromMR images
using manifold learning (ML) have been shown to contain valuable information about disease
severity and progression [28]. The main idea of ML is to find a meaningful, low-dimensional
representation of a high-dimensional feature space, such that similar scans also have similar
coordinates in the low-dimensional manifold. This is achieved in three steps. First, the image
regions that are most relevant with regard to information about disease progression are auto-
matically learned using sparse regression as in [37]. To compensate for varying intensity values
in the images caused by different scanners and acquisition protocols, local binary patterns
(LBP) are computed in a 26-connected neighbourhood for voxels within these regions and
used as features in the high-dimensional space. The manifold is then learned using Laplacian
eigenmaps. The local geometry is determined via a sparse similarity graph, built using the sum
of squared differences (SSD) as similarity measure. Connections in the graph are made between
the k nearest neighbours, with the additional constraint that an instance can only be connected
to one instance per subject.
The manifold coordinates are computed for all training subjects with at least 5 visits, which
results in 859 samples from 155 subjects available to train the models. The manifold is chosen
to have a dimension of d = 20, that means 20 features are obtained per subject per visit and
denoted with D1 to D20.
Results
Synthetic data
Evaluation based on synthetic data follows two main goals: A) to analyse how much the model
training based on quantile regression depends on the available data, and B) to demonstrate the
principle functionality of the presented approach for progress estimation.
Model reconstruction. The main interest of the model reconstruction is to analyse to
which degree VGAMs depend on the quantity of available training data. For all experiments,
the principle procedure is the following: First, a set of random samples is generated based on
the density functions defined by the synthetic models fMb. Then, these samples are used to esti-
mate the underlying model, yielding the reconstructed modelMb. Reconstruction accuracy is
assessed by comparing fMb toMb. As metric, the mean area between the corresponding den-
sity functions is regarded:
AREAb:¼ 1jPj
Z
P
Z
y
 fYbðyjpÞ  ~f YbðyjpÞ dy dp
To simulate the properties of the real data, the distribution of the samples on the domain P
requires special consideration. In particular, three sampling strategies are pursued:
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• Uniform sampling: The actual data structure is ignored and each sample is regarded inde-
pendently from the others, leading to a uniform sampling over P.
• Triangular sampling: For the model training based on real data, longitudinal time series are
aligned according to the point of conversion, which can be between any of the considered vis-
its. As a result, the density of samples decreases with the distance to p = 0. This effect can be
approximated by a triangular distribution of the samples over P. Note that by the ADNI pro-
tocol, subjects are only followed for a certain period of time after AD diagnosis and the distri-
butions are therefore not symmetric at p = 0. Still, each sample is regarded independently
from the others, which means that the variation of the PDF fYb is solely explained by noise in
the measurements.
• Longitudinal sampling: In this sampling approach, the variation in the density functions is
assumed to only account for inter-subject variations. That means, only the first sample in a
series of nV = 6 samples per subject is randomly distributed according to the noise model.
The following time points are sampled along the same quantile curve as the first sample with
q = qb(ys1, ps1).
The three sampling strategies are visualised in Fig 3. Real data can be assumed to lie some-
where between triangular and longitudinal sampling, as the variations are explained by a mix-
ture of inter-subject variability and noise.
With the real data pool in mind, four properties of the training set are in the focus of the
conducted experiments: 1) the number of samples, 2) the distribution of the samples over P, 3)
inaccuracies in the temporal alignment, and 4) variances in the progression rates of the sub-
jects. Further, the approach is compared to a competing model.
• Sensitivity to the number of samples: To analyse the influence of the number of samples on
the model training, the reconstruction procedure is executed with each sampling strategy for
nsmp = 100, 200, . . ., 1900 samples. The influence of randomness is reduced by running each
experiment nruns = 100 times. The mean errors and the 25th and 75th percentiles are—exem-
plarily forMCDRSBðpÞ—plotted in Fig 4A. It is observed that the estimation drastically
improves until about 500 samples are reached, then slowly converges and reaches a stable
level at around 1500 samples. Equally, the variation due to randomly chosen samples
decreases. Regardless of the number of samples, uniform sampling performs slightly better
than the triangular sampling, against which the longitudinal sampling converges at around
1500 samples.
Fig 3. Illustration of 100 random samples generated using uniform (left), triangular (center) and
longitudinal (right) sampling. The underlying model fMCDRSB is shown in blue.
doi:10.1371/journal.pone.0153040.g003
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• Sensitivity to the sampling strategy: To better assess the influence of the sampling strategy,
the results of the first experiment are visualised for all models in Fig 4B. Here, models are
learned based on 1000 samples, which approximately corresponds to the number of measure-
ments available for the real data. The trend “longitudinal>> triangular> uniform” persists,
especially with regard to the variation. However, the influence of the specific model out-
weighs this effect, withMCDRSBðpÞ being the worst reconstructed model andMHVðpÞ the
best.
• Robustness against misalignment: In this work, the time of conversion t0s is assumed to be in
the center between the last MCI and the first AD diagnosis. However, in real data it can be
everywhere between these two visits. Moreover, the diagnoses can be erroneous (or, more
precisely, the threshold at which a subject is classified as AD inconsistent), which entails a
more severe misalignment. To analyse the influence of this, the progress psv associated with
the samples (longitudinal sampling) is disturbed before model generation by adding artificial
noise, meaning psv δs + psv, where δs is sampled from a Gaussian distribution with μ = 0
and σ 2 [0, 200, 400]. The results are given in Fig 4C. While the influence of noise with σ =
200 is only marginal, a decline in accuracy can be observed for σ = 400. Still, the difference
between the models is much higher than the influence of noise.
• Sensitivity to different progression rates: Lastly, subjects are all assumed to progress with the
same rate in the model estimation approach, while in reality considerable differences in the
progression speed can be observed [3]. Therefore, similarly to the preceding experiment,
noise is added on the samples using psv δs  psv. Here δs is Gauss-distributed with μ = 1 and
σ 2 [0.0, 0.1, 0.2]. The results depicted in Fig 4D show no considerable difference between
the different noise levels, for neither of the biomarkers.
Fig 4. To measure the influence of the data pool on the model training, the sensitivity of quantile
regression using VGAMs to different properties of the sampling set is analysed. The graphs show the
mean reconstruction error after 100 cycles of random sample generation and model training. The numbers
above the boxes indicate the median error. (A) Sensitivity to the number of samples. (B) Sensitivity to the
sampling strategy. (C) Robustness against temporal misalignment. (D) Sensitivity to different progression
rates.
doi:10.1371/journal.pone.0153040.g004
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• Comparison to competing model: In addition, the estimated models are compared to the
approach presented by Donohue et al. [22]. This approach was chosen for several reasons.
First, both methods share the property that no assumptions on the shapes of trajectories are
made besides smoothness (and, in case of [22], monotony). Second, an open source imple-
mentation of Donohue’s model is available (http://mdonohue.bitbucket.org/grace/), which
allows a comparison based on the same set of samples. Finally, the approach stands exem-
plarily for methods that do not require a diagnosis for pre-alignment and are therefore not
susceptible to mis-diagnosis.
For this reason, models have been built for the data used in Fig 4C (100 runs, 1000 samples,
longitudinal sampling, σ 2 [0, 400]). As only the mean trajectories and not the quantile
curves are estimated by [22], the average difference between the mean trajectories is regarded
as metric. Without relying on the clinical diagnosis as input data, Donohue’s approach allows
a good reconstruction of the three modelsMHV,MCDRSB andMMMSE with mean differ-
ences of 60.6, 0.59 and 0.77 units. Assuming knowledge of the correct clinical diagnosis (i.e.,
σ = 0), VGAM’s provides a more precise reconstruction with mean errors of 42.7, 0.146 and
0.264 units. Simulating mis-diagnosis by introducing an error on the temporal alignment,
errors increase (42.5, 0.181, and 0.293 units for σ = 400) but are still considerably smaller
than for Donohue’s model.
Progress estimation. The accuracy of the model reconstruction regarded in the preceding
section does not allow any conclusion about the suitability of the models for estimating the dis-
ease progression (even though it obviously is a prerequisite): A perfectly reconstructed model
that does not change with p contains no information regarding the DP. Therefore, the focus of
this section is on quantifying the accuracy of progress estimation. To this end, ntest random test
samples are generated in the same way as the training samples, using uniform sampling over P.
These samples are then fitted to the model using Eq (4) to estimate the disease progress that
corresponds to the sample. The mean error between the estimated progress and the progress
assumed during sampling is regarded as metric.
• Correlation between model reconstruction and estimation accuracy: First, the disease prog-
ress is estimated for ntest = 100 individual single-biomarker samples with a search space of
[−3500, 2500] (which considerably exceeds the domain of the model). For this, the models
learned for Fig 4B are employed. In each run, a new set of test samples is generated to com-
pensate for the effect of randomness. The mean errors are illustrated in Fig 5A. While the dif-
ferences between the models is quite striking withMCDRSBðpÞ being superior to the other
models, the influence of the sampling strategy is negligible.
• Estimation with multiple biomarkers: In all preceding experiments, single biomarker values
were fitted to the corresponding models. Here, the influence of multiple measurements is
analysed, which can stem either from multiple visits or the simultaneous consideration of
multiple biomarkers. Therefore, the samples of the individual biomarkers are merged and fit-
ted to the multi-biomarker model by regarding the joint probability. Moreover, the experi-
ments are repeated with samples from 3 and 5 visits, while using longitudinal sampling for
sample generation. The results are displayed in Fig 5B. As can be seen, the estimation accu-
racy greatly improves with the number of biomarkers and visits.
Real data
Complementary to the experiments on synthetic data, this section is to evaluate the presented
approach based on biomarkers derived from clinical image data. First, progression models are
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trained for all considered biomarkers based on the ADNI data. These models are then
employed to estimate DP and DPR for all test subjects. Since the ground truth is unknown, the
meaningfulness of the estimated values is indirectly assessed by employing them in three exem-
plary applications: progress estimation for classification, construction of a 4D atlas of disease
progression, and the prediction of biomarker values.
Model training. Progression models are trained for all 60 regarded biomarkers. The (sin-
gle-threaded) quantile regression using VGAM takes approximately 15 seconds computation
time per biomarker on a standard desktop computer. Exemplary results are visualised in Fig 6.
Since the ground truth of the models is unknown, the focus is on quantifying how well the
trained models are suited to discriminate between different stages of disease. For this purpose,
a model should optimally have a large slope and a small variance. Let yb :¼ min p2Pyb0:5ðpÞ and
ybþ :¼ max p2P yb0:5ðpÞ be the minimum and maximum values of the median trajectory of the
model. The interval Y0:5 :¼ ½yb; ybþ then indicates the range of values for which the highest
probability lies within P. A large range indicates that the peaks of the density functions fY are
far apart from each other and thus distinctive. Further, the q-quantiles qbðyb; pÞ and qbðybþ; pÞ
that correspond to the values yb and y
b
þ are regarded. The distance q
b
þðpÞ  qbðpÞ indicates the
ratio of the samples with a value that lies within Y0.5. A high ratio implies a small variation of
the density functions an thus a discriminative model. The total discriminativeness of the model
is quantiﬁed as:
DISCb :¼ 1jPj
Z
P
qbðybþ; pÞ  qbðyb; pÞdp:
In Table 2, the 10 most discriminative models are listed together with the metric DISCb.
Analogous to the experiments on synthetic data, the estimated models are compared to the
approach presented by Donohue et al. [22] using same training data. For transferring the mod-
els to the same coordinate system, a temporal offset is optimally determined by minimising the
model difference (here: 300 days). The resulting models are visualised in Fig 6.
Progress estimation. The disease progress of all test subjects is estimated as presented.
Since the ground truth is unknown, plausibility of the estimated DPs is evaluated with regard
to their ability to differentiate between the diagnoses, that means to what extend an ordering of
CN< EMCI< LMCI< AD is achieved. To this end, p^0s is estimated on the search space
[−3500, 2500] for all CN, EMCI, LMCI and AD subjects in the test set using several biomarker
Fig 5. To illustrate the functionality of progress estimation for synthetic data, the mean estimation
errors are computed based on a set of ntest = 100 randomly generated test samples. The figures show
the mean errors for nruns = 100 runs of the experiments. The models correspond to the models analysed in
Fig 4B. (A) Sensitivity to the sampling strategy. (B) Influence of additional data frommore visits and multiple
biomarkers.
doi:10.1371/journal.pone.0153040.g005
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conﬁgurations. On the one hand, different sets of biomarkers Best are considered for estima-
tion: Bcog, Bvol, Bml, the imaging-based biomarkers Bimg := Bvol [ Bml, and all biomarkers united
Ball := Bcog [ Bimg. On the other hand, biomarkers from one (baseline), two (baseline and m12)
and three (baseline, m12 and m24) visits Vest are employed. The distribution of the estimated
DPs depending on the diagnosis is visualised in Fig 7.
Application: Classification based on disease progress. One of the main research topics
of image-based analysis of Alzheimer’s disease is the classification of subjects according to their
diagnosis based on structural MRI scans. This is underlined by a classification challenge held
Fig 6. Examples for progressionmodels of several biomarkers learned based on the ADNI data base.
Visualised biomarkers are: Mini—mental State Examination (MMSE), the Alzheimer’s Disease Assessment
Scale, 2013 (ADAS13), the Clinical Dementia Rating—Sum of Boxes (CDR-SB), the Functional Activities
Questionnaire (FAQ), volumes of right hippocampus, amygdala and lateral ventricle, as well as the first and
sixth manifold coordinates D1 and D6. In blue, models generated using the approach of Donohue et al. are
shown for comparison [22].
doi:10.1371/journal.pone.0153040.g006
Table 2. Ranking of the 10 most discriminative progressionmodels.D1 and D2 denote the first two ML coordinates.
Rank Biomarker b DISCb Rank Biomarker b DISCb
1. FAQ 0.776 6. ADAS11 0.697
2. CDRSB 0.764 7. MMSE 0.651
3. D1 0.747 8. Left Amygdala 0.480
4. ADAS13 0.714 9. Right Hippocampus 0.431
5. D2 0.714 10. Left Hippocampus 0.404
doi:10.1371/journal.pone.0153040.t002
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in the course of MICCAI 2014 conference, at which 15 international groups participated with
total of with 29 algorithms [38].
Therefore, the estimated DPs are used for a two-class classification between CN and AD,
CN and MCI, MCI and AD, as well as EMCI and LMCI. With only one feature, classification
breaks down to finding an optimal threshold pthresh that separates one group from the other.
For this test, the cognitive scores are excluded because the diagnosis is made largely based on
the CDR, such that including them biases the classification (e.g., classification accuracy reaches
1.0 for CN vs. AD and 0.96 for MCI vs. AD using cog). The average results of 100 runs of a
10-fold cross-validation are shown in Table 3.
Fig 7. Visualisation of the disease progress (DP) estimated with different biomarkers. The x-axes show
the disease progress in days before/after the conversion to AD. In the three columns, data from one, two and
three visits is employed. The rows show results based on the different biomarker sets. The red bars indicate
the median and 25th/75th percentile of the estimated DPS.
doi:10.1371/journal.pone.0153040.g007
Table 3. Results for a classification based on the DP as single feature, which is estimated using image-based biomarkers (see Fig 7). The numbers
indicate the mean accuracy (ACC), sensitivity (SENS) and specificity (SPEC) after 100 runs of a 10-fold cross-validation.
Biomarkers Visits CN vs. AD CN vs. MCI MCI vs. AD EMCI vs. LMCI
Best Vest ACC SENS SPEC ACC SENS SPEC ACC SENS SPEC ACC SENS SPEC
Bvol {bl} 0.78 0.81 0.77 0.66 0.64 0.70 0.66 0.64 0.67 0.51 0.42 0.74
{bl, m12} 0.80 0.82 0.79 0.66 0.66 0.67 0.68 0.66 0.68 0.52 0.38 0.87
{bl, m12, m24} 0.81 0.78 0.82 0.66 0.65 0.67 0.68 0.68 0.68 0.54 0.40 0.87
Bml {bl} 0.84 0.82 0.85 0.69 0.66 0.72 0.73 0.72 0.73 0.53 0.43 0.79
{bl, m12} 0.87 0.84 0.88 0.66 0.61 0.76 0.74 0.69 0.76 0.57 0.51 0.74
{bl, m12, m24} 0.88 0.87 0.89 0.65 0.56 0.79 0.71 0.69 0.72 0.56 0.49 0.73
Bimg {bl} 0.84 0.88 0.83 0.68 0.64 0.74 0.69 0.74 0.67 0.54 0.45 0.75
{bl, m12} 0.87 0.86 0.87 0.68 0.63 0.75 0.71 0.80 0.69 0.57 0.48 0.79
{bl, m12, m24} 0.89 0.89 0.89 0.67 0.60 0.79 0.70 0.80 0.68 0.58 0.50 0.78
doi:10.1371/journal.pone.0153040.t003
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Application: 4D atlas construction. Anatomical shape and appearance atlases play an
important role in the representation of populations of subjects and in the quantitative analysis
of variations between them. Spatio-temporal (4D) atlases additionally provide information
about physiological processes and have been applied in particular to study brain development
in paediatrics [39], neonatology [40], and in ageing [41]. In these applications, the subject’s age
at the time of image acquisition is generally considered as the temporal dimension. Further,
powerful techniques exist to analyse anatomical changes over time caused by ageing or AD.
These include (but are not limited to) statistics on temporal deformations [27], multivariate
regression to explore relations between shape and clinical response [42], or regional flux analy-
sis using Helmholtz decomposition of stationary velocity fields [43]. Lorenzi et al. further pres-
ent an approach to disentangle normal ageing from pathological changes. Such methods
allow to gain valuable information about characteristics of disease-related morphological
changes [44].
In this section, however, the main goal is to visually assess validity of the estimated DPs by
constructing a spatio-temporal atlas of the disease progress and identifying deformations typi-
cal for AD. To this end, the bias-free atlas construction proposed by Serag et al. [45] is
employed, using DP instead of age to determine the temporal variable. First, the DP is esti-
mated for all MCI and AD subjects in the training set using all biomarkers Best = Ball at three
timepoints Vest = {1, 2, 3} (here, baseline, m12 and m24), which coincides with the last experi-
ment in Fig 7. The baseline scans are then ordered according to their DP (instead of their age)
and adaptive kernel regression is employed to construct the atlas. To compute the mean geom-
etry at a specific disease progress p, only subjects with a DP close to p are considered and their
weighted average is computed as detailed in [45] (with the only difference that a symmetric dif-
feomorphic registration approach [46] is employed for an intrinsic availability of the inverse
transformation).
The constructed 4D atlas of the brain degeneration is visualised in Fig 8 for p 2 [−3000,
−2000, −1000, 0, 1000] days.
Application: Prediction of biomarker values. As initially motivated, an important
requirement for clinicians is the prediction of the future course of disease, in particular the cog-
nitive and functional decline. Here, the development of biomarker values is predicted based on
the approach for DP and DPR estimation. In detail, the values ybsv of a biomarker b are assumed
to be known for subject s for three timepoints tsv, with v 2 Vest = {1, 2, 3}. Based on these sam-
ples, the value ybs4 at ts4 is predicted. To do so, three prediction approaches are compared:
• Naive prediction: A naive prediction is employed as reference approach. Here, a linear model
ybs ðtÞ :¼ mt þ as is fitted to the three observations, where the slope m is the average change of
the biomarker values in the course of one year, which is estimated on all MCI and AD sub-
jects. It is then as ¼  13
P
vðmtsv  ybsvÞ. The predicted biomarker value is given by
~ybs4 ¼ ybs ðts4Þ.
• DP-based prediction: For a model-based prediction, the DP is estimated for s—corresponding
to the last column in Fig 7—using all three visits and a biomarker set Best. Note that bmight
or might not be included in Best. From a practical point of view, it makes sense to always con-
sider b if values are available, however, it is not done here to be able to correlate the predic-
tion results with the progress estimation shown in Fig 7. Based on the estimated processes
psv ¼ tðp^0s ; tsvÞ, the mean quantile curve
qs ¼
1
3
X3
v¼1
qbðybsv; psvÞ
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is then determined. The value ybs4 is assumed to lie on the mean quantile at ts4, that means
~ybs4 ¼ ybqsðps4Þ
• DP/DPR-based prediction: To also account for the progression rate of s, the same approach is
repeated with the affine time warp definition Eq (6), that means psv ¼ tðp^0s ; r^s; tsvÞ
Fig 9, shows sketches to illustrate these three approaches. Further, some exemplary results are
given in Fig 10. The prediction errors jybs4  ~ybs4j for the CDR-SB and MMSE (indicating cogni-
tive decline), FAQ (functional decline) and the volume of the right hippocampus (to show the
versatility of the approach) using different biomarker sets are given in Fig 11. These results are
based on all AD and MCI subjects for which ybs4 is additionally available for evaluation, result-
ing in 77 subjects.
Discussion
Synthetic data
The experiments on synthetic data demonstrate that VGAMs are suitable for reconstructing
the probability density functions of a progression model, given a sufficient number of samples.
Fig 8. The generated 4D atlas depicting the the progression of Alzheimer’s disease, disentangled
from the normal ageing of the subjects.
doi:10.1371/journal.pone.0153040.g008
Fig 9. Concept of naive (left), DP- (center) and DP/DPR-based (right) prediction of biomarker values.
doi:10.1371/journal.pone.0153040.g009
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Fig 10. Illustration of observed (filled circles) and predicted (outlined circles) biomarker values for six
randomly picked and representative subjects. The slope of the naive linear prediction approach is
visualised with a dashed line with ybs ðtÞ at the end. In a solid line, the quantile curve qs is shown. The ﬁtted
progression model is shown in light grey.
doi:10.1371/journal.pone.0153040.g010
Fig 11. Results for the prediction of future biomarker values for four different biomarkers (tree
cognitive scores and the hippocampal volume). The prediction of the value at m36 is based on bl, m12
and m24 visits, using the ADNI data. Bold median values indicate a statistically significant improvement over
the naive approach (p < 0.01).
doi:10.1371/journal.pone.0153040.g011
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In this context, nsmp	 1000 appears to be adequate to compensate for the effect of the longitu-
dinal sampling. However, more samples could decrease the impact of randomness. It is further
observed that the reconstruction error increases with the distance from p = 0 due to the lower
density of samples. The dependence on long biomarker sequences—this means, sequences of
samples acquired during as many visits as possible—is therefore given for two reasons: On the
one hand, to extend the interval P on which the model is learned and on the other hand, to
increase the density of samples at the end points and thereby decrease the reconstruction error
in these regions. In practice, this requirement limits the applicability of the model learning pro-
cedure to rather large data sets like ADNI.
In the experiments, the influence of temporal misalignment and in particular different pro-
gression rates of the training subjects was small and negligible. This was especially apparent
when analysing the estimation error, because the disciminativeness of the specific model clearly
outweighs the impact of the reconstruction error. For example, while a considerable influence
of the sampling strategy on the reconstruction is apparent in Fig 4B, no considerable difference
of the estimated DPs is observed in Fig 5A.
In contrast to the model presented by Donohue et al. [22], the presented approach relies on
a clinical diagnosis for pre-alignment. The comparison of both methods shows that this addi-
tional information can be exploited by VGAM’s for a more precise model reconstruction.
While this also implies that the approach is susceptible for mis-diagnosis, the increase in accu-
racy outweighed the errors introduced by a reasonable degree of misalignment in the
experiments.
Adding further information in the form of more biomarker measurements or data from
multiple visits significantly increases the accuracy of progress estimation. As shown in Fig 5B,
even the hardly discriminative models for MMSE and HV contribute to the overall accuracy
when combined with the CDR-SB.
Real data
Turning to the real data, the models learned using quantile regression and illustrated in Fig 6
produce plausible biomarker trajectories. Cognitive scores and volumetric biomarkers exhibit
sigmoidal or near-linear shapes, confirming the observations made, for example, in [11] and
[22]. The generated models are similar to the models of Donohue et al.; the mean error is
between 0.5% (right cerebral wight matter) and 7.7% (CDR-SB), normalised with the maximal
absolute value of the mean trajectory. In some cases, the sigmoidal-shaped models of Donohue
et al. exhibit unrealistically large slopes at the boundary of the model domain (cf. right amyg-
dala) or are not able to capture the shape of ml-based biomarkers (cf. D6). However, missing a
ground truth, a quantitative comparison of the models’ correctness cannot be given.
In the biomarker ranking shown in Table 2, all five cognitive scores are amongst the most
discriminative biomarkers and only the first two manifold coordinates perform similarly well.
This finding is reasonable because cognitive scores exhibit a smaller inter-subject variability
than, for example, the absolute volumes of brain structures. On the other hand, the good rank-
ing of Bcog could also point to a potential bias in these models: Since diagnosis in the ADNI
protocol is heavily dependent on MMSE and CDR, these scores are implicitly used for temporal
alignment of the training subjects. However, due to the fact that MMSE is not significantly bet-
ter ranked than the other scores (in fact, it is slightly worse), we hypothesise that a potential
bias introduced hereto can be assumed to be small.
A further potential bias is introduced by the temporal alignment. Since this step is only
based on converters, the models do not represent the whole population if converters progress
differently in the disease than non-converters (not only faster), or if certain biological (brain
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reserve, age) or genetic (APoE-4 presence) factors differ between the two subgroups. While
this can be seen as a drawback of the model, constraining the data pool to converters to AD is
consistent with the intention to model the progression of Alzheimer’s Disease and therefore
assumed to be justified.
A major advantage of the presented approach lies within the fact that all available training
samples can be used for learning, even if the total number of samples varies from model to
model. This enables an optimal usage of the data (as seen for the synthetic data, more samples
entail a better fitting) because, for example, a subject’s CDR-SB score could be used even
though no MMSE was acquired. In contrast to that, other common machine learning
approaches would be restrained to the set of subjects for which all considered biomarkers are
available.
The DPs estimated for the test subjects and shown in Fig 7 show a good class separation. In
general, the cognitive scores perform best for distinguishing between the four classes. Regard-
ing the image-based features, Bml outperforms the volumetric measurements for MCI/AD sep-
aration because these suffer from the large inter-subject variability. Adding more time points
slightly improves the results, mainly by enhancing the robustness of the estimate. This can be
attributed to the fact that 24 months are—compared to the whole course of disease—a rela-
tively short period of time. In this context, the results for data with a DP not contained in the
training set are of particular interest: Using the cognitive and volumetric biomarkers, the
majority of CN subjects are correctly clustered at p = −3500, that means at the beginning of the
search space, even though no control subjects were considered for model learning. Also, early
and late MCI subjects have distinct means at p< −1500, that means in the extrapolated region.
This implies that the model extrapolation is well-suited for Bcog and Bvol, whose trajectories are
monotonically increasing or decreasing functions—as propagated, for example, in [18]. How-
ever, this does not hold true for the manifold coordinates, which don’t exhibit this “natural”
shape. Extending these models to regions outside the training set remains subject of future
research.
These findings are supported by the results for image-based classification shown in Table 3.
In general, results CN vs. AD classification (accuracy/sensitivity/specificity up to 0.89/0.89/
0.89) using the disease progress as a single feature are on par with recent publications like [47]
(reported sensitivity/specificity: up to 0.82/0.89) or [48] (reported accuracy/sensitivity/specific-
ity: 0.89/0.93/0.85). Keeping in mind that slightly different subject sets are used and results are
therefore not fully comparable, this demonstrates the potential of the DP to capture as much
information about the disease state as the underlying biomarkers. Since the model is focussing
on the MCI-to-AD phase, MCI vs. AD classification is considerably better than CN vs. MCI
classification. This means, class separation suffers from less accurate modelling of early disease
progression, which highlights the potential benefit of extending models to the CN-to-MCI
phase.
The applicability of the estimated DPs for the construction of a spatio-temporal atlas of the
disease progression has been successfully shown. As illustrated in Fig 8, the 4D atlas exhibits
the expected patterns as an increasing volume of the ventricles and hippocampal atrophy.
Further, DPs and DPRs have been employed successfully to predict biomarker values, in
particular the expected cognitive decline of a subject. Model-based prediction outperforms the
naive approach for all biomarkers considered with only one exception (prediction of the hippo-
campal volume based on Bvol). Considering the progression rate further improves the predic-
tion. This holds true for all biomarkers used for DP/DPR estimation, however, the cognitive
scores generally perform best. An interesting finding is that the manifold coordinates provide
the best DP (and DPR) estimation to predict the hippocampal volume. This is intriguing
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because due to the feature selection, the manifold is learned on a region around the hippocam-
pus and it can be assumed that specific manifolds could be learned for certain prediction tasks.
As in the training phase, a particular advantage of the progress estimation is that all avail-
able data can be utilised without retraining the model. It is, for example, possible to estimate
the DP if only cognitive scores are available for one visit and only image-based biomarkers for
another visit. In this way, all available information can be employed in an intrinsic way.
Outlook
While the presented method enables the combination of the information contained in all avail-
able measurements, it still relies on the definition of meaningful biomarkers. In this context, it
would be interesting to employ biomarkers based on atrophy [49], tensor-based morphometry
[13] or PET imaging [50], which could be integrated in a straightforward manner.
Currently, samples of subjects that are potentially suffering from terminal decline (36 of the
248 training subjects deceased during the study due to AD or another unknown cause) are not
excluded from model training. While first experiments indicate a minor impact, it has not yet
been analysed quantitatively if terminal decline impairs model training.
In the current approach for pre-alignment, only disease progress of the training subjects is
aligned and not the progression rates. While this could be tackled in future versions of the
model, preliminary experiments with an iterative pre-alignment techniques suggest that the
effect is only marginal. Further, as discussed above, the pre-alignment introduces a potential
bias in the progression models by considering the diagnosis and limiting the data pool to con-
verters. In principle, however, the pre-alignment step is generic and any other suitable
approach could be employed.
During progress estimation, the probabilities of all biomarkers values are assumed to be
independent of each other, this means fY(ysv1, ysv2|τ(ts)) = fY(ysv1|τ(tsv1))  fY(ysv2|τ(tsv2)) for v1 6¼
v2. This is a simplification because the variation of biomarker values is hypothesised to be com-
posed of inter-subject variability and noise. Accordingly, a value ysv2 has a higher probability to
lie on the quantile curve of ysv1, which should be considered in a future model. Similarly, the
independence across biomarkers is a simplified assumption, as dependencies between bio-
markers exist, e.g. between ADAS 11 and ADAS13 scores.
In a related matter, intra-subject variability—which is particularly apparent for cognitive
scores—is not explicitly modelled in the current approach. An enhanced modelling incorporat-
ing, for example, random effects would therefore be desirable.
A further challenge is extending the model domain P to a longer temporal span. In princi-
ple, the same approach could be employed to learn models for CN to MCI converters. A com-
bination of the CN/MCI and MCI/AD models is therefore highly desirable and first steps in
this direction have already been presented in [26]. Together with the use of further imaging
biomarkers, this could potentially enhance the exploration of early disease progression, which
is of particular clinical relevance because medication is most effective in the pre-symptomatic
phase [13].
Besides prolonging the temporal span of the models, another approach would be to define a
multi-dimensional progression domain P. This would relate, for example, to Stallard et al. [9],
who split disease progression into cognitive, clinical, and functional progression. Similarly,
incorporating age as a further covariate would allow a more realistic modelling compared to
the currently implemented linear regression. However, these extensions would pose high
demands on the size of the data set used for model training.
Given enough training data, it would also be highly interesting to generate specific models
for certain subject groups, for example male and female or APoE-4 positive and negative
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subjects, which have a different age at disease onset [11]. Such personalised models could not
only lead to a considerably improved progress estimation and allow further insights into the
disease, but also address potential biases introduced by the temporal alignment.
Finally, the approach was only tested for analysing the progression of Alzheimer’s Disease.
Potentially, other kinds of dementia or completely unrelated diseases could be regarded as well.
The only requirement is the availability of meaningful biomarkers.
Conclusion
In this work, an approach for biomarker-based disease progression modelling based on quan-
tile regression was presented. The trained models were then employed to estimate the disease
progress and the disease progression rate of test subjects. A main advantage of the method is
that missing data is naturally handled, that means it can be employed even if the available bio-
markers vary between the visits, without requiring a retraining of the model.
The presented experiments demonstrate the employment of the proposed method for dis-
ease estimation in several clinical applications, which range from classification over 4D atlas
construction to the model-based prediction of biomarker values. The main focus of future
work is on the extension of the model domain, which will allow a more precise estimation of
early disease progression.
An open-source Python implementation of the presented method for progression modelling
and the evaluation is available under https://github.com/aschmiri/DiseaseProgressionModel.
Appendices
A1 Model extrapolation
To extend the progression modelling to stages outside the interval P = [p−, p+], the model is
extrapolated by extending the underlying predictor functions η(p) using exponential functions.
These are chosen such that the derivatives at the end points p± equal η0(p±). Further, scaling
factors D
Z deﬁned by D


Z :¼ jZð0Þ  Zðp
Þj (i.e., depending on the amount of change of η in
the MCI and AD intervals, respectively) are introduced, such that η(p) converges against
Zðp
Þ 
 sgnðZ0ðp
ÞÞD
Z for p! ±1. This results in sigmoid-like shaped predictor functions.
The ﬁnal formulation for eZðpÞ is then given by
eZðpÞ :¼
ZðpÞ  sgnðZ0ðpÞÞDZ 1 exp jZ
0ðpÞj
DZ
ðp pÞ
 h i
p < p
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DþZ
ðpþ  pÞ
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h i
p > pþ
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The model extrapolation is illustrated in A1 Figs 12 and 1C.
A2 Brain structures
Volumes of the following 35 brain structures are considered as biomarkers Bvol: 3rd Ventricle,
4th Ventricle, Left/Right Accumbens Area, Left/Right Amygdala, Brain Stem, Left/Right Cau-
date, Left/Right Cerebellum Exterior, Left/Right CerebellumWhite Matter, Left/Right Cerebral
White Matter, CSF, Left/Right Hippocampus, Left/Right Inferior Lateral Vent, Left/Right Lat-
eral Ventricle, Left/Right Pallidum, Left/Right Putamen, Left/Right Thalamus Proper, Left/
Right Ventral Diencephalon, Cerebellar Vermis, Left/Right Basal Forebrain, Left/Right Cortex.
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